Trial Profile
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms Induction Study #1
- Sponsors Celgene Corporation; Celgene International SARL
- 06 Apr 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 29 Mar 2024 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 28 Mar 2024 Primary endpoint has not been met. (Proportion of participants with a Crohns Disease Activity Index (CDAI) score 150), according to a Bristol Myers Squibb media release.